INTRODUCTION
Initial treatment with tyrosine kinase inhibitors (TKIs) induces an excellent response in most patients with chronic myeloid leukemia in chronic phase (CML-CP) and leads to an expected survival approaching that of the general population. [1] [2] [3] [4] [5] [6] [7] [8] A randomized clinical trial of 1106 patients using frontline imatinib versus interferon-a plus cytarabine showed a 5-year overall survival (OS) rate of 89% (95% confidence interval [CI] , 86%-92%), and no patients who achieved a major molecular response (MMR) within 12 months progressed to an accelerated or blast phase at 60 months. 9 The European LeukemiaNet (ELN) guidelines recommend periodic monitoring of BCR-ABL1 at 3, 6, and 12 months with real-time polymerase chain reaction (PCR); they define an optimal response as BCR-ABL1 transcript levels 10% on the international scale (IS) at 3 months, < 1% at 6 months, and 0.1% from 12 months onward and treatment failure as BCR-ABL1 transcript levels > 10% at 6 months and > 1% from 12 months onward. 10 During the course of treatment, recognizing early predictors of a deeper response and longer term outcomes can help to guide treatment. This is relevant not only at the specified fixed time points typically reported (ie, 3, 6 , and 12 months) but at any other time during the course of therapy.
The achievement of a sustained deep molecular response is a goal of increasing relevance because it opens the possibility of treatment discontinuation. The Australasian Leukaemia and Lymphoma Group CML8 (TWISTER) reported an estimated stable treatment-free remission rate of 47% (95% CI, 32%-63%) at 24 months of imatinib discontinuation in patients with a sustained molecular response with BCR-ABL1 level <0.0032% on the international scale (MR 4.5 ) for 2 or more years before discontinuation. 11 With a median follow-up of 20.0 months (interquartile range [IQR], 16.5-24.0 months), the Dasatinib Discontinuation (DADI) trial reported a treatment-free remission rate of 49% (95% CI, 36%-61%) at 6 months in patients who received at least 1 year of consolidation dasatinib therapy after the achievement of a deep molecular response. 12 The objective of this study was to investigate optimal BCR-ABL1 transcript levels at any given time that predict for a sustained MR 4.5 (BCR-ABL1 level 0.0032% for at least 2 years) according to BCR-ABL1 levels achieved within the first 12 months of TKI therapy.
MATERIALS AND METHODS

Study Design and Participants
We reviewed response data for 630 consecutive patients with newly diagnosed CML-CP who were enrolled in consecutive or parallel prospective clinical trials of frontline TKIs between July 30, 2000, and November 25, 2014, at a single institution: imatinib (n 5 73; NCT00048672), high-dose imatinib (n 5 208; NCT00038649 and NCT00050531), nilotinib (n 5 148; NCT00129740), dasatinib (n 5 150; NCT00254423), and ponatinib (n 5 51; NCT01570868). Patients with only qualitative BCR-ABL1/ABL1 during the first year of therapy or with transcript type b3a3 or e1a2 or an unknown type were excluded from the analysis. A total of 603 patients were included in the analysis: imatinib (n 5 52), high-dose imatinib (n 5 205), nilotinib (n 5 147), dasatinib (n 5 148), and ponatinib (n 5 51). The inclusion criteria were similar for all trials and included an age 16 years, adequate heart, liver, and renal function, and a performance status of 0 to 2. TKI therapy consisted of imatinib (with a starting dose of 400 or 800 mg daily, alone or with pegylated interferon after 6 months of single-agent high-dose imatinib), dasatinib (50 mg twice daily or 100 mg once daily), nilotinib (400 mg twice daily), or ponatinib (45 or 30 mg daily).
3,4,13-15 All protocols were approved by the institutional review board at The University of Texas MD Anderson Cancer Center, and written informed consent was obtained in accordance with the Declaration of Helsinki.
Procedures
Detailed information about protocol-specific procedures can be found in the original reports and at ClinicalTrials.-gov. 3, 4, [13] [14] [15] An analysis was performed for the following response categories: complete cytogenetic response (CCyR) within 1 year, MMR within 1 year, and sustained MR 4.5 at any point. A sustained MR 4.5 was defined as an MR 4.5 in all consecutive assessments performed every 6 months for at least 2 years. Quantitative real-time PCR analysis was performed at approximately 3-month intervals during the first year and at 6-month intervals thereafter. BCR-ABL1 levels that were missing because samples were inadequate or not taken were excluded from the analysis. The response criteria were according to the standard definitions 10 : MMR (BCR-ABL1 level 0.1% on the IS) and MR 4.5 (BCR-ABL1 level 0.0032% on the IS). Baseline BCR-ABL1 levels were excluded from our analysis because of the upper limit of BCR-ABL1 levels at 100%, which skewed the true baseline BCR-ABL1 levels and did not accurately reflect the biological nature of the disease status.
Outcomes
We estimated the probability of survival by response group with the Kaplan-Meier method. The definitions of OS, event-free survival (EFS), transformation-free survival (TFS), and failure-free survival (FFS) were previously published. 16 The probability of a sustained MR 4.5 was estimated with the inverted Kaplan-Meier method.
Statistical Analysis
BCR-ABL1 data were significantly skewed near undetectable BCR-ABL1 levels (Supporting Fig. 1 [see online supporting information]) and were logarithm-transformed for further analysis (Fig. 1A) . The best fit average molecular response was defined with robust linear regression models, with which the average molecular levels that predicted the achievement of a CCyR within 1 year, an MMR within 1 year, and a sustained MR 4.5 at any point were defined. The minimum acceptable molecular response was defined by quantile regression for the 95th percentile, with which the BCR-ABL1 levels detected in at least 95% of the patients who ultimately achieved a CCyR within 1 year, an MMR within 1 year, and a sustained MR 4.5 at any point were identified. Univariate comparisons for survival were performed with a log-rank test in which 2-tailed P values less than .05 were considered statistically significant. To validate this approach for the prediction of a deep molecular response, the whole patient cohort was then randomly divided into 2 cohorts: a training cohort (80% of the total cohort) for creating a model and a validation cohort (20% of the total cohort). The accuracy of prediction was assessed for each target response in the validation cohort with Fisher's exact test or the chi-square test. We performed statistical analyses with the R statistical software system (version 3.3.1) or SPSS software (version 23; SPSS, Inc, Chicago, Illinois). The best fit average PCR values (ie, the estimated levels achieved by the average responder in each category) were 0.087%, 0.037%, 0.016%, and 0.007% at 3, 6, 9, and 12 months, respectively, for a CCyR within 1 year and 0.059%, 0.024%, 0.010%, and 0.004% at 3, 6, 9, and 12 months, respectively, for an MMR within 1 year. For the achievement of a sustained MR 4.5 at any point, the best fit average PCR values were 0.051%, 0.019%, 0.007%, and 0.003% on the IS at 3, 6, 9, and 12 months, respectively ( Table 2 ). To achieve a CCyR within 1 year, the minimum acceptable PCR values (ie, the levels achieved by 95% of all those who eventually reach the target endpoint) were 2.218%, 1.485%, 0.994%, and 0.665% on the IS at 3, 6, 9, and 12 months, respectively; to achieve an MMR within 1 year, the values were 1.127%, 0.553%, 0.271%, and 0.133% on the IS, respectively. The minimum acceptable PCR values for eventually achieving a sustained MR 4.5 at any time during the course of therapy were 1.561%, 0.592%, 0.225%, and 0.085% on the IS at 3, 6, 9, and 12 months, respectively. There were 282 patients who eventually achieved a sustained MR 4.5 ; within 1 year of the start of therapy, 280 (99%) had achieved a CCyR, 268 (95%) had achieved an MMR, 201 (71%) had achieved a molecular response with a 4-log reduction on the international scale [BCR-ABL1 level <0.01% on the IS (MR 4 )] and 162 (57%) had achieved an MR 4.5 . Of the 358 patients who achieved an MMR within 1 year and had a minimum follow-up of 48 months, 256 (72%) achieved a sustained MR 4.5 . This is in contrast to 14 of the 96 (15%) who had not achieved an MMR at 1 year. Similarly, 151 of the 180 patients (84%) who achieved an MR 4.5 within 1 year eventually achieved a sustained MR 4.5 , whereas 119 of the 274 patients (43%) who had not achieved an MR 4.5 within 1 year did. The median times to a sustained MR 4.5 were 71.0, 60.2, 53.2, and 36.6 months for all patients and for those who 2) . Of the 52 patients on imatinib at 400 mg/d, 40 (77%) and 32 (62%) achieved a CCyR and an MMR, respectively, within 1 year. The corresponding values were 185 (90%) and 164 (80%) of the 205 patients on imatinib at 800 mg/d, 113 (76%) and 67 (45%) of the 148 patients on dasatinib, 130 (88%) and 114 (78%) of the 147 patients on nilotinib, and 48 (94%) and 41 (80%) of the 51 patients on ponatinib (P 5 .035 and P 5 .077).
RESULTS
In
The 5-and 10-year clinical outcomes are described in Table 3 and Figure 3 . FFS decreased by approximately 12% between 5 and 10 years, regardless of the response, mostly because of discontinuation due to toxicity; TFS was minimally changed over this same 5-year period, whereas EFS and OS decreased by approximately 6% from the 5-year time point to the 10-year time point. The 5-and 10-year OS rates for the whole cohort were 94% and 86%, respectively. The corresponding figures were 95% and 88% for those with a CCyR within 1 year, 95% and 89% for those with an MMR within 1 year, and 98% and 92% for those with a sustained MR 4.5 . The whole cohort was then divided into a training cohort (484 patients) and a validation cohort (119 patients). The patient characteristics, types of frontline TKIs, and responses are described in Supporting Table 2 (see online supporting information) for the 2 subcohorts. The best fit average and minimum acceptable levels were calculated with the training cohort (Supporting Fig. 2 , Table 3 [see online supporting information]). Probability of sustained MR 4.5 is described in Supporting Fig. 3 . The 5-and 10-year FFS, TFS, EFS, and OS rates are described in Supporting Table 4 , Fig. 4 (see online supporting information). Overall, the accuracy of the prediction with the best fist average and minimum acceptable levels of BCR-ABL1 was well validated (Supporting Table 5 [see online supporting information]). With the minimum acceptable levels, each cutoff at 3, 6, 9, and 12 months adequately separated patients who achieved or did not achieve each target response. All the patients who met the best fit average criteria achieved a sustained MR 4.5 , and the majority of the patients with the achievement of minimum acceptable levels achieved a sustained MR 4.5 .
DISCUSSION
To our knowledge, this is the first analysis of best fit average and minimum acceptable BCR-ABL1 levels to achieve specific response endpoints in patients with newly diagnosed CML-CP. The best fit average molecular levels represent the typical transcript levels of patients who achieved each target response, and the minimum acceptable molecular levels represent the 95th percentile levels in target responders. It is well documented that achieving a CCyR and an MMR significantly improves the life expectancy of patients, whether this is achieved with interferon therapy or any of the TKIs currently available.
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The ELN defined optimal and warning BCR-ABL1 levels at 3, 6, and 12 months. 10 Our findings of minimum acceptable levels for an MMR within 1 year (1.127%, 0.553%, and 0.133% on the IS at 3, 6, and 12 months, respectively) are similar to those proposed for optimal response categories without a logarithmic difference by the ELN (ie, BCR-ABL1 levels 10%, 1%, and 0.1 on the IS at 3, 6, and 12 months, respectively). Similarly, our proposed minimum acceptable levels for a CCyR within 1 year (2.218%, 1.485%, and 0.665% at 3, 6, and 12 months, respectively) are consistent with ELN warning BCR-ABL1 levels (10%, 1%-10%, and 0.1%-1% on the IS at 3, 6, and 12 months, respectively). It should be noted that our models for the best fit average and minimum acceptable levels were derived from time points around 3, 6, 9, and 12 months. It is possible that the estimated values of the best fit average and minimum acceptable levels between time points could be less accurate because of the smaller number of data samples. However, the deviation from each exact time point allowed our analysis to make reliable predictions between time points. As shown in Figure 1 , the best fit average and minimum acceptable levels reliably represent the average levels and 95th percentile levels in each response category. In actual practice, our model could be useful for evaluating warning and optimal BCR-ABL1 levels at any time point during the course of therapy and not only at the exact time points proposed by the ELN recommendations.
There is a growing interest in TKI discontinuation in patients who have achieved a stable deep response, that is, a sustained MR 4.5 . The prospective, multicenter Stop Imatinib (STIM) trial reported that 41% of patients who achieved complete molecular response for at least 2 years maintained the response at 12 months with at least 12 months' follow-up. 21 The TWISTER trial reported a treatment-free remission rate of 47% at 24 months for patients who had achieved a sustained MR 4.5 before imatinib discontinuation. 11 More recently, the DADI trial demonstrated a treatment-free remission rate of 49% at 6 months in patients after 1 year of consolidation therapy on dasatinib after the achievement of an MR 4.0 with a median follow-up of 20 months. 12 The ENEStop trial is from the name of the trial as "Treatment-free Remission After Achieving Sustained MR 4.5 on Nilotinib (ENESTop)" evaluated the discontinuation of nilotinib in 126 patients with CML-CP who achieved a deep molecular response with 1 year of nilotinib after imatinib, and it demonstrated that 58% of patients who stopped nilotinib maintained treatment-free remission at 48 weeks. 22 The ENESTFreedom is from the name of the trial "Nilotinib Treatment-free Remission Study in CML Patients (ENESTFreedom)" also showed that 52% of patients in deep remission remained treatment-free at 48 weeks after the discontinuation of nilotinib. 23 These results suggest that the expected outcome is similar, regardless of the TKI used before discontinuation, although the likelihood of achieving these responses may be higher with a second-generation TKI versus imatinib. We thus evaluated the best fit average and minimum acceptable molecular levels within 1 year of treatment to make predictions for the achievement of a sustained MR 4.5 at any point on the basis of the BCR-ABL1 levels achieved within the first year of TKI therapy. In this analysis, the best fit average level at 3 months for patients eventually achieving a sustained MR 4.5 was 0.051% (95% CI, 0.0306%-0.0844%). This means that the average patient who eventually achieved a sustained MR 4.5 had achieved at least an MMR (and nearly an MR 4 ) at 3 months. It is possible that the criteria are less restrictive for a sustained MR 4.5 at any time with longer follow-up. The minimum acceptable BCR-ABL1 level at 12 months for a sustained MR 4.5 was 0.085% (95% CI, 0.0202%-0.3594%). This means that nearly all patients (specifically 93%) who eventually achieved a sustained MR 4.5 had achieved an MMR (and nearly an MR 4 ) within 1 year. Although the higher end of the 95% CI (0.3594% on the IS) is higher than the MMR levels, it is important to note that the molecular levels at 1 year of TKI therapy need to be <0.4% for patients to have a reasonable probability of achieving a sustained MR 4.5 . Furthermore, 99% of the patients who achieved a sustained MR 4.5 had achieved a CCyR within 1 year. Thus, the achievement of a CCyR within 1 year of TKI treatment is nearly a sine qua non for the achievement of a sustained MR 4.5 at any time during the course of therapy. It is important to highlight that although this model can identify at early time points patients with a low probability of achieving specific goals later during the course of therapy, whether and what specific interventions may change the outcomes of such patients remain to be studied.
In our models, we described the estimated 12-month best fit average and minimum acceptable BCR-ABL1 levels with BCR-ABL1 data within 12 months of TKI therapy to predict the achievement of a CCyR and an MMR within 1 year as well as a sustained MR 4.5 at any point. The best fit average and minimum acceptable levels for a CCyR within 1 year were 0.007% and 0.665%, respectively; for an MMR within 1 year, the values were 0.004% and 0.133%, respectively. Although these endpoints might be considered of intermediate relevance (ie, surrogates of long-term outcomes rather than desired outcomes themselves), the estimated BCR-ABL1 levels at 12 months for a CCyR and an MMR within 1 year (ie, at a time when responses have actually already occurred) confirm the accuracy of the prediction in our analysis and support the idea that the prediction of a sustained MR 4.5 is feasible with our approach.
There are several limitations to our study. First, this is a single-institution cohort of patients enrolled in consecutive prospective clinical trials, and patients with significant comorbidities, including heart failure, chronic kidney disease, liver cirrhosis, and other active cancers, were excluded from clinical trials and thus were not included in this analysis. Thus, it is possible that the results are not representative of all patients with CML-CP. However, the protocols of each clinical trial accepted patients with common medical diseases such as hypertension, diabetes mellitus, and hyperlipidemia, a history of myocardial infarction, and a distant history of cancer and were generally more permissive than the large, pivotal trials with dasatinib or nilotinib and thus provide information applicable to patients more similar to the average patient. Also, the disease assessment and the follow-up timing were performed consistently for all protocols. We have reported that the outcomes of patients treated within or outside clinical trials with imatinib at our institution are equivalent, and the interpretation of BCR-ABL1 levels would not be influenced, regardless of clinical trials. 24 Second, the definition of a sustained MR 4.5 required at least 2 year of a stable MR 4.5 or a deeper response in our analysis. Patients who achieved deep remission with shorter follow-up were excluded from the analysis. It is possible that additional data from patients who would achieve a sustained MR 4.5 with longer follow-up might affect our analysis of the best fit average and minimum acceptable BCR-ABL1 levels. However, clinical trials with imatinib, high-dose imatinib, nilotinib, and dasatinib
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have adequately long follow-up, and further follow-up would not affect our results significantly. Third, we logarithmically transformed BCR-ABL1/ABL1 ratios, and this might lead to a potential bias. However, current ELN recommendations interpret the depth of a response with cutoffs at 10%, 1%, and 0.1% on the IS, which in essence represent 1-log declines. 25 The logarithmic decline of BCR-ABL1/ABL1 levels was used in our analysis at each time point. Thus, we analyzed our data to follow current monitoring guidelines. Fourth, baseline BCR-ABL1 levels were not included on account of a potential bias from the upper limit of BCR-ABL1 levels at 100% because the true biological nature of the disease status at diagnosis could exceed 100% of the BCR-ABL1 levels. The incorporation of baseline BCR-ABL1 levels without the upper limit might affect our results. However, the validation model confirmed that our approach could adequately separate patients for the target response with minimum acceptable cutoffs. Lastly, second-generation TKIs produced higher rates of deep responses, and these occurred faster than those with imatinib. 26, 27 However, the current agreement about the significance of cytogenetic and molecular responses according to the ELN recommendations is that the desired optimal responses and the values that define failure are the same at 3, 6, and 12 months and thereafter, regardless of the TKI. 10 Various analyses of outcomes based on responses suggest that the significance of given responses at specific times is similar, regardless of the TKI used, although generally second-generation TKIs may give a higher probability of responses, particularly earlier and deeper responses. Because the clinical significance of each response is treated equally, regardless of the TKI, a predictive model derived from the combined data for various TKIs is justifiable.
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